Vistagen Therapeutics Files 8-K
Ticker: VTGN · Form: 8-K · Filed: Sep 23, 2024 · CIK: 1411685
| Field | Detail |
|---|---|
| Company | Vistagen Therapeutics, Inc. (VTGN) |
| Form Type | 8-K |
| Filed Date | Sep 23, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-update, 8-K
TL;DR
Vistagen Therapeutics filed an 8-K on 9/23/24 updating corporate info.
AI Summary
On September 23, 2024, Vistagen Therapeutics, Inc. filed an 8-K report. The filing indicates that the company is a pharmaceutical preparations company incorporated in Nevada. The report details the company's principal executive offices located at 343 Allerton Ave., South San Francisco, California, 94080, with a contact phone number of (650) 577-3600.
Why It Matters
This 8-K filing provides an update on Vistagen Therapeutics' corporate information, including its address and contact details, which is important for investors and stakeholders to have the most current information.
Risk Assessment
Risk Level: low — This filing is a routine corporate update and does not appear to contain material financial or operational news.
Key Players & Entities
- Vistagen Therapeutics, Inc. (company) — Registrant
- Nevada (jurisdiction) — State of incorporation
- 343 Allerton Ave., South San Francisco, California, 94080 (address) — Principal executive offices
- 650-577-3600 (phone_number) — Registrant's telephone number
FAQ
What is the primary business of Vistagen Therapeutics, Inc.?
Vistagen Therapeutics, Inc. is in the Pharmaceutical Preparations industry, with Standard Industrial Classification code 2834.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on September 23, 2024.
What is the address of Vistagen Therapeutics, Inc.'s principal executive offices?
The principal executive offices are located at 343 Allerton Ave., South San Francisco, California, 94080.
What is the telephone number for Vistagen Therapeutics, Inc.?
The registrant's telephone number, including area code, is (650) 577-3600.
In which U.S. state is Vistagen Therapeutics, Inc. incorporated?
Vistagen Therapeutics, Inc. is incorporated in Nevada.
Filing Stats: 555 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-09-23 08:49:48
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share VTGN Nasdaq Capital Market
Filing Documents
- vtgn-20240923.htm (8-K) — 26KB
- vistagenpr-palx4initiation.htm (EX-99.1) — 18KB
- image_0.jpg (GRAPHIC) — 100KB
- 0001411685-24-000042.txt ( ) — 308KB
- vtgn-20240923.xsd (EX-101.SCH) — 2KB
- vtgn-20240923_lab.xml (EX-101.LAB) — 21KB
- vtgn-20240923_pre.xml (EX-101.PRE) — 12KB
- vtgn-20240923_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events On September 23, 2024, Vistagen Therapeutics, Inc. (the " Company ") issued a press release to announce that it has enrolled the first subject in its PALISADE-4 Phase 3 trial of fasedienol, the Company's investigational neuroactive pherine candidate in U.S. registration-directed Phase 3 development for the acute treatment of social anxiety disorder. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1. Disclaimer . The information in this Current Report on Form 8-K, including the information set forth in Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act" ), nor shall Exhibit 99.1 filed herewith be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits . (d) Exhibits Index Exhibit No. Description 99.1 Press Release issued by Vistagen Therapeutics, Inc., dated September 2 3, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
Signatures
Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Vistagen Therapeutics, Inc. Date: September 23, 2024 By: /s/ Shawn K. Singh Shawn K. Singh Chief Executive Officer